iBio, Mesoblast, Kodiak Sciences among healthcare movers
Seeking Alpha News (Thu, 28-Mar 10:01 AM ET)
Globe Newswire (Mon, 25-Mar 7:00 AM ET)
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
Globe Newswire (Mon, 26-Feb 8:00 AM ET)
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
Globe Newswire (Wed, 10-Jan 3:00 PM ET)
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.
Beyondspring - trades on the NASDAQ stock market under the symbol BYSI.
As of March 28, 2024, BYSI stock price declined to $3.51 with 62,201 million shares trading.
BYSI has a beta of 0.14, meaning it tends to be less sensitive to market movements. BYSI has a correlation of 0.00 to the broad based SPY ETF.
BYSI has a market cap of $137.39 million. This is considered a Micro Cap stock.
In the last 3 years, BYSI stock traded as high as $33.00 and as low as $.54.
The top ETF exchange traded funds that BYSI belongs to (by Net Assets): IWC.
BYSI has outperformed the market in the last year with a price return of +216.2% while the SPY ETF gained +33.7%. BYSI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +294.4% and +16.6%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
BYSI support price is $3.31 and resistance is $3.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BYSI stock will trade within this expected range on the day.